AstraZeneca Pharma India Receives Warning Letter from NSE Over Regulations

AstraZeneca Pharma India Ltd. has come under regulatory scrutiny after receiving a warning letter from the National Stock Exchange of India (NSE). The notice, issued on 7 February 2025, cites non-compliance with SEBI’s Listing Obligations and Disclosure Requirements (LODR). The company failed to meet the mandatory quorum for an audit committee meeting, prompting NSE to take the matter seriously.

Non-Compliance with SEBI Listing Regulations

According to NSE, AstraZeneca Pharma India did not adhere to Regulation 18(2)(b) of LODR during an audit committee meeting held on 27 May 2024. The regulation requires that the quorum for such meetings must include at least two independent directors. However, the meeting in question had only one independent director present, leading to a breach of compliance standards. NSE has emphasised that such violations will not be overlooked.

Corrective Measures and Future Compliance

Following this non-compliance, NSE has advised AstraZeneca Pharma India to take corrective actions and exercise greater caution in the future. The exchange has directed the company to ensure strict adherence to regulatory requirements to prevent further lapses.

Additionally, the company has been instructed to present the warning letter and the measures taken for rectification to its board of directors. NSE has also warned that any future deviations will be dealt with seriously and could lead to further regulatory action.

AstraZeneca Share Performance

As of February 11, 2025, at 2:30 PM, shares of AstraZeneca Pharma are trading at ₹7,424.90 per share, reflecting a decline of 1.62% from the previous day’s closing price. Over the past month, the stock has registered a surge of 5.11%.

Conclusion

AstraZeneca Pharma India Ltd. has been issued a warning by NSE for failing to comply with audit committee meeting regulations. The company is now required to take corrective steps and ensure full compliance with SEBI’s LODR to prevent further violations.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.